Alza
This article was originally published in The Tan Sheet
Executive Summary
Takes one-time, $28 mil. write-off in the fourth quarter of 1993 due to the "scale-up of the production of certain products and to excess transdermal manufacturing capacity and equipment" at the company's Vacaville, Calif. facility. Alza noted that sales of Nicoderm transdermal smoking-cessation products, which are marketed by Marion Merrell Dow, declined during 1993. The write- off is expected to result in a net loss for fourth quarter 1993. Separately, Alza names Exec VP-Business Development Adrian Gerber exec VP-commercial development, and VP-Corporate Planning and Analysis Bruce Cozadd as VP and chief financial officer
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning